IL-10 knockdown with siRNA enhances the efficacy of Doxorubicin chemotherapy in EBV-positive tumors by inducing lytic cycle via PI3K/p38 MAPK/NF-kB pathway

High levels of IL-10 expression in Epstein–Barr virus (EBV) associated tumors have been reported and it is likely to be important for maintaining EBV latency and EBV-associated tumors. The switch from the latent form of EBV to the lytic form in tumor cells can lead to tumor cell lysis. Here, we foun...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer letters 2019-10, Vol.462, p.12-22
Hauptverfasser:	Gao, Li, Han, Haige, Wang, Honglei, Cao, Li, Feng, Wen-hai
Format:	Artikel
Sprache:	eng
Schlagworte:	1-Phosphatidylinositol 3-kinase Activation AKT protein Animals Antibiotics, Antineoplastic - pharmacology Apoptosis BZLF1 protein Cell growth Cell Proliferation Chemotherapy Doxorubicin Doxorubicin - pharmacology EBV reactivation EBV-Associated tumors Epstein-Barr virus Epstein-Barr Virus Infections - complications Epstein-Barr Virus Infections - virology Herpesvirus 4, Human - physiology Humans IL-10 silencing Infections Inhibition Interleukin 10 Interleukin-10 - antagonists & inhibitors Interleukin-10 - genetics Kinases Latency Lipids Lymphoma Lysis MAP kinase Mice Nanoparticles NF-kappa B - genetics NF-kappa B - metabolism NF-κB protein p38 Mitogen-Activated Protein Kinases - genetics p38 Mitogen-Activated Protein Kinases - metabolism Phosphatidylinositol 3-Kinases - genetics Phosphatidylinositol 3-Kinases - metabolism Phosphorylation Proteins RNA, Small Interfering - genetics Signal transduction Signal Transduction - drug effects siRNA Stomach Neoplasms - drug therapy Stomach Neoplasms - genetics Stomach Neoplasms - pathology Stomach Neoplasms - virology Tumor cells Tumor Cells, Cultured Tumors Vascular endothelial growth factor VEGF Virus Activation - drug effects Virus Activation - genetics Viruses Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!